Patents Issued in June 26, 2018
  • Patent number: 10004714
    Abstract: The present disclosure relates to compositions, methods and devices for treating, reducing or preventing one or more eye disorders, particularly dry eye disorders, in a subject by administering an amount of one or more fatty acids and/or fatty acid esters therapeutically effective to inhibit lipase activity while permitting bacterial growth or without substantially altering the dynamic microbial community of the eye. Typically, the fatty acids and/or fatty acid esters are C8 to C16 fatty acids and/or fatty acid esters.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: June 26, 2018
    Assignee: Brien Holden Vision Institute
    Inventors: Hua Zhu, Judith Louise Flanagan
  • Patent number: 10004715
    Abstract: Obesity is inhibited by administering to a person in need thereof an effective amount of entacapone ((2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide), or a pharmaceutically-acceptable salt thereof, particularly in conjunction with a second, different anti-obesity medicament. Pharmaceutical compositions comprise entacapone copackaged or coformulated with a second, different anti-obesity medicament.
    Type: Grant
    Filed: January 4, 2014
    Date of Patent: June 26, 2018
    Assignee: National Institute of Biological Sciences, Beijing
    Inventors: Niu Huang, Gang Zhi, Jijie Chai, Shiming Peng, Nannan Hou
  • Patent number: 10004716
    Abstract: A method for prophylactically or therapeutically treating an inflammatory disease and/or degenerative intervertebral disk disease in a subject is disclosed. The method includes administering to the subject an effective amount of a coumarin derivative represented by formula (I), or a pharmaceutically acceptable salt or hydrate thereof: Each of R1 and R2 is independently (a) phenyl optionally substituted with alkoxy, alkyl, cyano, nitro, hydroxy, trifluoromethyl, amino, carboxy, alkoxycarbonyl, phenyl, or one or two halogen(s), (b) pyridyl, (c) alkyl, or (d) thienyl.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: June 26, 2018
    Assignee: NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventors: Mitsuru Naiki, Takumi Numazawa, Hiroki Fujisawa
  • Patent number: 10004717
    Abstract: Salts of glycopyrrolate, including solid forms and formulations such as topicals thereof, are disclosed. Methods of making glycopyrrolate salts, including formulations such as topicals thereof, and methods of treating hyperhidrosis with salts of glycopyrrolate, and formulations such as topicals thereof, are disclosed.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: June 26, 2018
    Assignee: DERMIRA, INC.
    Inventors: John Allan Statler, Anthony Adrian Shaw, Delphine Caroline Imbert, Jennifer Leigh Nelson, Patricia Andres, Lisa Lynn McQueen, Stephan Xander Mattheus Boerrigter, Jon Gordon Selbo, Mark Christopher Andres
  • Patent number: 10004718
    Abstract: The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R3 is OH.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: June 26, 2018
    Assignees: Tohoku University, Kake Education Institution, Kanagawa Prefectural Hospital Organization Kanagawa Children's Medical Center
    Inventors: Takaaki Abe, Teiji Tominaga, Kenichiro Hayashi, Hitoshi Osaka
  • Patent number: 10004719
    Abstract: A spray-dried solid dispersion containing a pharmaceutical compound of formula (I) shown below and a pharmaceutically acceptable polymer, in which the pharmaceutical compound is dispersed in a polymer matrix formed from the pharmaceutically acceptable polymer. Further disclosed are methods for preparing such a solid dispersion and using it for treating hepatitis C virus infection and a pharmaceutical formulation containing same.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: June 26, 2018
    Assignee: TaiGen Biotechnology Co., Ltd.
    Inventors: Ming-Chu Hsu, Chu-Chung Lin, Chi-Hsin Richard King
  • Patent number: 10004720
    Abstract: It is an object of the present invention to provide a novel medicament for preventing and/or treating ophthalmologic diseases caused by ocular angiogenesis. According to the present invention, provided is a medicament for preventing and/or treating ophthalmologic diseases caused by ocular angiogenesis, which comprises, as an active ingredient, a pyrazolone derivative such as 3-methyl-1-phenyl-2-pyrazolin-5-one, or a physiologically acceptable salt thereof, or a hydrate thereof or a solvate thereof.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: June 26, 2018
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Hideaki Hara, Masamitsu Shimazawa, Tomomi Masuda
  • Patent number: 10004721
    Abstract: A pharmaceutical composition comprises at least one integrase inhibitor or its salt, solvate, complex, hydrate, isomer, ester, tautomer, anhydrate, enantiomer, polymorph or prodrug and at least one antiretroviral or anti-HIV agent or its salt, solvate, complex, hydrate, isomer, ester, tautomer, anhydrate, enantiomer, polymorph or prodrug.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: June 26, 2018
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Shrinivas Purandare
  • Patent number: 10004722
    Abstract: Pharmaceutical compositions of the invention include novel functionalized 1,3-benzenediols having a disease-modifying action in the treatment of hepatic encephalopathy and related conditions. Pharmaceutical compositions of the invention further include novel neuroprotective agents.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: June 26, 2018
    Assignee: KANNALIFE SCIENCES, INC.
    Inventors: Douglas E. Brenneman, William Alvin Kinney, Mark McDonnell, Dean Petkanas
  • Patent number: 10004723
    Abstract: An intravaginal device that provides biologically active circulating concentrations of an aromatase inhibitor for at least about of 4 days. Liposome-based and a wax-based formulations were used to assess letrozole diffusion through bovine vaginal mucosa in a diffusion chamber study. The wax-based vehicle was selected for further development of a letrozole intravaginal device based on its steady release rate. The addition of a letrozole-containing gel coating improved initial absorption and hastened the increase on plasma concentrations of the active ingredient, while the letrozole-containing wax-based vehicle maintained prolonged delivery from the intravaginal device.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: June 26, 2018
    Assignee: University of Saskatchewan
    Inventors: Gregg Patrick Adams, Maria Jimena Yapura, Roger A. Pierson, Ildiko Badea
  • Patent number: 10004724
    Abstract: A compound according to formula (I) wherein R1 is hydrogen, cyclopropyl, or pyrazolyl, wherein said pyrazolyl is optionally substituted by one or two methyl groups; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: June 26, 2018
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew Anderson, Matthew Howard James Campbell-Crawford, Ashley Paul Hancock, Seble Lemma, Simon John Fawcett MacDonald, John Martin Pritchard, Panayiotis Alexandrou Procopiou, Stephen Swanson
  • Patent number: 10004725
    Abstract: This disclosure relates to use of certain aldehyde compounds for treating pulmonary fibrosis, hypoxia, and connective tissue and autoimmune disease such as scleroderma, lupus, arthritis and related conditions in a mammal.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: June 26, 2018
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Kobina N. Dufu, Xin Geng, Uma Sinha
  • Patent number: 10004726
    Abstract: Polymorphs, Forms II and III, of cocrystals of p-coumaric acid and nicotinamide in a 1:1 molar ratio. Pharmaceutical compositions containing Forms II or III, processes for making such forms, and methods of treatment with such Forms.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: June 26, 2018
    Assignee: AMRI SSCI, LLC
    Inventors: Melanie Janelle Bevill, Nate Schultheiss
  • Patent number: 10004727
    Abstract: The present invention relates to a novel use of a composition containing, as an active ingredient, an amodiaquine compound or a pharmaceutically acceptable salt thereof and specifically, to a metabolic disease prevention, alleviation or treatment use of a composition containing, as an active ingredient, an amodiaquine compound or a pharmaceutically acceptable salt thereof, the composition activating both peroxisome proliferator-activated receptor-gamma (PPAR-?) and peroxisome proliferator-activated receptor-alpha (PPAR-?).
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: June 26, 2018
    Assignees: POSTECH ACADEMY-INDUSTRY FOUNDATION, NOVMETAPHARMA CO., LTD.
    Inventors: Kyong Tai Kim, Hoe Yune Jung
  • Patent number: 10004728
    Abstract: Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating broncho-obstructive and inflammatory diseases.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: June 26, 2018
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Fabio Rancati, Andrea Rizzi, Laura Carzaniga, Ian Linney, Chris Knight, Wolfgang Schmidt
  • Patent number: 10004729
    Abstract: Tamper-resistant pharmaceutical compositions have been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. The tamper-resistant compositions retard the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: June 26, 2018
    Assignee: COLLEGIUM PHARMACEUTICAL, INC.
    Inventors: Roman V. Rariy, Alison Fleming, Jane C. Hirsh, Said Saim, Ravi K. Varanasi
  • Patent number: 10004730
    Abstract: A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from: (a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or (b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: ?wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; R21 is an alkanediyl or a substituted alkanediyl; a is 0 or 1; c is 0 or 1; X is C or S; R22 is a moiety that includes at least one divalent amino radical; and R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: June 26, 2018
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Zhou Wang, Joel Byron Nelson, Minh Bao Nguyen, John S. Lazo, Paul A. Johnston, Peter Wipf
  • Patent number: 10004731
    Abstract: The invention relates to the use of Flibanserin for the treatment or prevention of urinary incontinence and related diseases. In a further embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment or prevention of urinary incontinence and related diseases.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: June 26, 2018
    Inventors: Ramiro Castro, Angelo Ceci
  • Patent number: 10004732
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: June 26, 2018
    Assignee: Novartis AG
    Inventors: Benjamin Richard Bellenie, Graham Charles Bloomfield, Ian Bruce, Andrew James Culshaw, Edward Charles Hall, Gregory John Hollingworth, James Neef, Matthew Spendiff, Simon James Watson
  • Patent number: 10004733
    Abstract: The invention relates to new pyridopyrazine derivative compounds of formula (I-A) or formula (I-B): to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: June 26, 2018
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Valerio Berdini, Gordon Saxty, Patrick Rene Angibaud, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet, Bruno Roux, Lieven Meerpoel
  • Patent number: 10004734
    Abstract: The present disclosure provides methods and compositions for treating or preventing erythema, including rebound erythema associated with the use of topical alpha-adrenergic agonists. In certain embodiments, an effective amount of a capsaicinoid, such as capsaicin or a pharmaceutically acceptable salt or derivative thereof, is administered to a subject.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: June 26, 2018
    Inventor: Warren Scherer
  • Patent number: 10004735
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount a second active agent to a patient having a cancer.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: June 26, 2018
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Kimberly Elizabeth Fultz, Tam Minh Tran, Shuichan Xu, Weiming Xu
  • Patent number: 10004736
    Abstract: The present invention relates to methods of preventing or treating skin necroptosis diseases, including administering to subjects receptor-interacting protein kinase-3 (RIP3)-mixed lineage kinase domain-like protein (MLKL) pathway blockers or dabrafenib, and method of diagnosing of skin necroptosis diseases, including detecting phosphorylated MLKL. The RIP3-MLKL pathway blockers according to the present invention directly suppress RIP3 overexpressing in skin necroptosis diseases, or inhibit phosphorylation and translocation to plasma membranes of MLKL, subsequently induced therefrom, thereby effectively preventing skin cell death via necroptosis. Thus, the present invention can prevent or treat a variety of skin diseases caused by necroptosis.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: June 26, 2018
    Assignee: Ajou University Industry-Academic Cooperation Foundation
    Inventor: You Sun Kim
  • Patent number: 10004737
    Abstract: A series of substituted benzimidazole, imidazo[1,2-?]pyridine and pyrazolo[1,5-?]pyridine derivatives, and analogs thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: June 26, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Julien Alistair Brown, Mark Daniel Calmiano, Elizabeth Pearl Jones, Boris Kroeplien, James Thomas Reuberson, Matthew Duncan Selby, Michael Alan Shaw, Zhaoning Zhu
  • Patent number: 10004738
    Abstract: The present invention is directed to the combined use of BACE1 inhibitor of Formula I and a compound useful in active or passive Tau immunotherapy, a compound useful in active or passive A? peptide immunotherapy, an NMDA receptor antagonists, an acetylcholine esterase inhibitor, an antiepileptic, an anti-inflammatory drug, a Tau aggregation inhibitor or an SSRI for the treatment of neurodegenerative or cognitive disorders.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: June 26, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Karsten Juhl, Mauro Marigo, Lena Tagmose, Thomas Jensen
  • Patent number: 10004739
    Abstract: The present invention aims to elucidate a polynucleotide as a novel responsible gene for cancer and aims to thus provide a method for detecting the polynucleotide and a polypeptide encoded by the polynucleotide and a detection kit, a probe set, and a primer set for the detection. The present invention also aims to provide a pharmaceutical composition for treating cancer. The method detects a fusion gene composed of a portion of an FGFR3 gene and a portion of a TACC3 gene or a fusion protein encoded by the fusion gene. The primer set, the probe set, or the detection kit comprises a sense primer and a probe set designed from the portion encoding FGFR3 and an antisense primer and a probe set designed from the portion encoding TACC3. Since an inhibitor of the polypeptide exhibits antitumor effect, a pharmaceutical composition for treating cancer which is positive for either the fusion gene or the polypeptide is provided.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: June 26, 2018
    Assignee: Astellas Pharma Inc.
    Inventors: Atsushi Suzuki, Makoto Asaumi, Kazuhisa Tsunoyama, Kouichi Nishimura, Akifumi Morinaka, Tomohiro Yamauchi, Masayasu Yoshino, Hiroaki Yoshizaki
  • Patent number: 10004740
    Abstract: Compounds of Formula I are described: wherein R1 and R2 are defined herein. The compounds of Formula I are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV, and the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: June 26, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher S. Burgey, Jeffrey F. Fritzen, Jaume Balsells, Mehul Patel
  • Patent number: 10004741
    Abstract: The present invention provides a solid form and composites thereof, which are useful as an inhibitor of EGFR kinases and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: June 26, 2018
    Assignee: Celgene CAR LLC
    Inventor: Mei Lai
  • Patent number: 10004742
    Abstract: Methods are provided of treating a human for cancer comprising administering at least one dose of lapatinib, or a pharmaceutically acceptable salt or composition thereof, to a patient, wherein said patient does not have one or more allelic polymorphisms selected from the group of: HLA-DQA1*0201, HLA-DQB1*0202, and HLA-DRB1*0701. Patients may also be free of genotypes in TNXB; rs12153855 and/or rs17207923.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: June 26, 2018
    Assignee: Novartis AG
    Inventors: Nan Bing, Linda Perry Briley, Laura R. Parham, Charles J. Cox, Colin F. Spraggs
  • Patent number: 10004743
    Abstract: The present invention relates to a drying process of BIBW 2992 or the salts thereof, preferably the dimaleate salt, as well as of solid pharmaceutical formulations comprising BIBW2992 or a salt thereof, and to pharmaceutical compositions comprising BIBW 2992 or a salt thereof as the active product ingredient, characterized by a water activity of the formulation of not more than 0.20 or a water content (Karl-Fischer) of not more than 4.2%.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: June 26, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Albert Barta
  • Patent number: 10004744
    Abstract: The present invention relates to compositions and methods for the treatment of Parkinson's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Parkinson's disease and related disorders targeting the alpha-synuclein aggregation network. In particular, the invention relates to compounds which, alone or in combination(s), can effectively protect neuronal cells from alpha-synuclein aggregates. The invention also relates to methods of producing a drug or a drug combination for treating Parkinson's disease and to methods of treating Parkinson's disease or a related disorder.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: June 26, 2018
    Assignee: Pharnext
    Inventors: Daniel Cohen, Serguei Nabirochkin, Ilya Chumakov
  • Patent number: 10004745
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: June 26, 2018
    Assignee: Pharmacyclics LLC
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Patent number: 10004746
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: June 26, 2018
    Assignee: Pharmacyclics LLC
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Patent number: 10004747
    Abstract: The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: June 26, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Klein, Rolf Grempler, Michael Mark
  • Patent number: 10004748
    Abstract: Methods and compositions are provided for treating breast cancer in patients with a PI3K inhibitor, GDC-0941 in combination with an endocrine therapy agent.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: June 26, 2018
    Assignee: Genentech, Inc.
    Inventors: Mika K. Derynck, Lori Friedman, Steven Brian Gendreau, Sandra Milan
  • Patent number: 10004749
    Abstract: The present disclosure provides a safe method for anesthesia or the treatment of pain by safely administering an amount of active agent to a patient while reducing the incidence or severity of suppressed respiration. The present disclosure provides a pharmaceutical composition comprising a therapeutic agent and a chemoreceptor respiratory stimulant. In one aspect, the compositions oppose effects of respiratory suppressants by combining a chemoreceptor respiratory stimulant with an opioid receptor agonist or other respiratory-depressing drug. The combination of the two chemical agents, that is, the therapeutic agent and the respiratory stimulant, may be herein described as the “drugs.” The present compositions may be used to treat acute and chronic pain, sleep apnea, and other conditions, leaving only non-lethal side effects.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: June 26, 2018
    Inventor: John Hsu
  • Patent number: 10004750
    Abstract: The present invention provides an acid addition salt or a sodium salt of a compound represented by the formula (IA): or their hydrate or a stable crystalline solid thereof. The salt or the crystalline solid is extremely useful as an active ingredient for the production of a pharmaceutical product.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: June 26, 2018
    Assignee: Shionogi & Co., Ltd.
    Inventors: Fumihiko Matsubara, Takanori Kurita, Daiki Nagamatsu
  • Patent number: 10004751
    Abstract: The present disclosure provides methods of treating a flavivirus infection, and compositions for use in the methods.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: June 26, 2018
    Assignees: The J. David Gladstone Institutes, The Regents of the University of California
    Inventors: Melanie Ott, Andrew S. Kondratowicz, Nevan John Krogan, Priya Shirish Shah, Krystal Ann Fontaine
  • Patent number: 10004752
    Abstract: An adapter for a tripodal stereotactic reference frame for use in arthroplastic surgery mounts a third leg of the frame at an angle with respect to the other two legs to facilitate use of said frame with varying surgical exposures.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: June 26, 2018
    Inventor: Stephen B. Murphy
  • Patent number: 10004753
    Abstract: The present disclosure provides methods of reducing the level of acetylated Tau in a neuron or a glial cell in an individual, the methods involving administering to the individual a prodrug that is converted in the individual to salicylate. The present disclosure provides methods of treating a tauopathy in an individual, the methods involving administering to the individual a prodrug that is converted in the individual to salicylate.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: June 26, 2018
    Assignee: The J. David Gladstone Institutes
    Inventors: Li Gan, Xu Chen, Min Xie, Eric M. Verdin
  • Patent number: 10004754
    Abstract: A therapeutic method for treating and/or preventing diseases and medical conditions typically treated by administering diuretic agents (eg congestive heart failure). The method may comprise, for example, administering to a subject a diuretic agent in combination with vessel dilator (VSDL) or a variant or modified peptide thereof. The administration of the diuretic agent may be a component of a standard of care (SOC) treatment.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: June 26, 2018
    Assignee: Madeleine Pharmaceuticals Pty Ltd.
    Inventor: Thomas Robert Geimer
  • Patent number: 10004755
    Abstract: Uses of pyrrolopyrimidines with anti-Mer tyrosine kinase activity as anti-infective agents, immunostimulatory and immunomodulatory agents, anti-cancer agents (including against MerTK?/? tumors and ITD and TKD mutant forms of Acute Myeloid Leukemia (AML)), and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: June 26, 2018
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Xiaodong Wang, Weihe Zhang, Stephen Frye
  • Patent number: 10004756
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: June 26, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10004757
    Abstract: An oral, nonprescription supplement is described which may contain coenzyme Q10, niacin, and lecithin. The supplement may be sold over-the-counter and is intended to improve cardiovascular health. In use, the supplement is to be taken with a food item and to be further taken twice (two times) per twenty-four hour period.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: June 26, 2018
    Assignee: Nutri Vida, LLC
    Inventor: Donna Vining
  • Patent number: 10004758
    Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: June 26, 2018
    Assignee: Rempex Pharmaceuticals, Inc.
    Inventors: Gavin Hirst, Raja Reddy, Scott Hecker, Maxim Totrov, David C. Griffith, Olga Rodny, Michael N. Dudley, Serge Boyer
  • Patent number: 10004759
    Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL). In the preferred embodiment the drug in the solubilizing agent is mixed with the liposomes in aqueous suspension so that the concentration of solubilizing agent is lowered to below its capacity to completely solubilize the drug. This results in the drug precipitating but remote loading is capability retained.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: June 26, 2018
    Assignee: ZONEONE PHARMA, INC.
    Inventors: Mark E. Hayes, Charles O. Noble, Francis C. Szoka, Jr.
  • Patent number: 10004760
    Abstract: The present invention relates to a microbubble complex comprising a microbubble having an outer shell comprising a mixture of native and denatured albumin encapsulating a perfluorocarbon gas, a therapeutic agent, a bifunctional linker having one end attached to the therapeutic agent and the other attached to a ligand and wherein the ligand is bound to the other shell of the microbubble through hydrophobic interactions. Also included are methods for delivering the aforementioned microbubble complex to a tissue target.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: June 26, 2018
    Assignee: GENERAL ELECTRIC COMPANY
    Inventors: Praveena Mohan, Anup Sood, James Edward Rothman, John Donald Burczak, Hae Won Lim, Lisa Anne Lowery
  • Patent number: 10004761
    Abstract: A composition suitable for treating a variety of medical, aesthetic and cosmetic conditions in mucous membranes and occluded skin areas, comprising hyaluronic acid, N-acetylcysteine, an active agent and set to pH of less than 6, which is characterized by high in vivo stability, is disclosed, as well as uses thereof in temporally extended delivery of active agent to mucous membrane in bodily sites.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: June 26, 2018
    Inventors: Mark M. Levy, Zvi Nevo, Samuel Levin
  • Patent number: 10004762
    Abstract: The invention relates to a dialysis formulation, optionally a citrate containing dialysis formulation, comprising selenium (Se), optionally in combination with further trace elements selected from rubidium (Rb), cobalt (Co), molybdenum (Mo), and zinc (Zn). The dialysis formulation is intended to be used in dialysis treatment.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: June 26, 2018
    Assignee: GAMBRO LUNDIA AB
    Inventors: Anna Bryland, Ola Carlsson, Karin Sandin
  • Patent number: 10004763
    Abstract: An object of the present invention is to provide magnesium oxide that can be preferably used for pharmaceutical applications or as a food additive. In particular, the object is to provide magnesium oxide granules with which tableting problems and quality defects can be reduced, and in more particular, to provide magnesium oxide granules with which tableting problems and quality defects can be reduced and which has less heavy metal incorporation and high purity of magnesium oxide. Provided are magnesium oxide granules for pharmaceutical applications or for addition to food having a BET specific surface area of 7 to 50 m2/g and CAA80/CAA40 of 2 to 7.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: June 26, 2018
    Assignee: KONOSHIMA CHEMICAL CO., LTD.
    Inventor: Kensho Sakamoto